Literature DB >> 3813516

Protection of mice from lethal influenza virus infection with high dose-short duration ribavirin aerosol.

P R Wyde, S Z Wilson, B E Gilbert, R H Smith.   

Abstract

An aerosol generated from a reservoir containing 60 mg of ribavirin per ml given for 2 h twice daily for 4 days afforded the same high level of protection against lethal influenza virus infection of mice as a longer, conventional treatment schedule (20 mg/ml given for 11 h daily for 4 days). Incremental decreases in ribavirin concentration made while maintaining the 2-h intermittent schedule provided progressively less protection of mice. Mice exposed to the 60-mg/ml doses had significantly increased pulmonary and serum drug levels when compared with mice given 20 mg of drug per ml, these increases were transient, and no evidence of pulmonary intolerance was detected. These studies suggest that protective effects of ribavirin against influenza virus infection can be achieved without untoward effects if higher doses and shorter periods of administration are used.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3813516      PMCID: PMC180625          DOI: 10.1128/AAC.30.6.942

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Amantadine small-particle aerosol: generation and delivery to man.

Authors:  S Z Wilson; V Knight; R Moore; E W Larson
Journal:  Proc Soc Exp Biol Med       Date:  1979-07

2.  Ribavirin treatment of viral pneumonitis in severe combined immunodeficiency disease.

Authors:  E W Gelfand; D McCurdy; C P Rao; P J Middleton
Journal:  Lancet       Date:  1983-09-24       Impact factor: 79.321

3.  Treatment of influenza A (H1N1) virus infection with ribavirin aerosol.

Authors:  S Z Wilson; B E Gilbert; J M Quarles; V Knight; H W McClung; R V Moore; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

4.  Ribavirin small-particle aerosol treatment of influenza.

Authors:  V Knight; H W McClung; S Z Wilson; B K Waters; J M Quarles; R W Cameron; S E Greggs; J M Zerwas; R B Couch
Journal:  Lancet       Date:  1981-10-31       Impact factor: 79.321

5.  Treatment of respiratory viral infection in an immunodeficient infant with ribavirin aerosol.

Authors:  K McIntosh; S C Kurachek; L M Cairns; J C Burns; B Goodspeed
Journal:  Am J Dis Child       Date:  1984-03

6.  Effects of low- and high-passage influenza virus infection in normal and nude mice.

Authors:  P R Wyde; R B Couch; B F Mackler; T R Cate; B M Levy
Journal:  Infect Immun       Date:  1977-01       Impact factor: 3.441

7.  Clinical evaluation of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) in a double-blind study during an outbreak of influenza.

Authors:  F Salido-Rengell; H Nasser-Quinones; B Briseno-Garcia
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

8.  Limited efficacy of aerosolized recombinant alpha interferon against virulent influenza A/HK infection in mice.

Authors:  C S Sun; S Z Wilson; P R Wyde
Journal:  Proc Soc Exp Biol Med       Date:  1986-02

9.  Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice.

Authors:  S Z Wilson; V Knight; P R Wyde; S Drake; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

10.  Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants.

Authors:  L H Taber; V Knight; B E Gilbert; H W McClung; S Z Wilson; H J Norton; J M Thurson; W H Gordon; R L Atmar; W R Schlaudt
Journal:  Pediatrics       Date:  1983-11       Impact factor: 7.124

View more
  12 in total

Review 1.  Aerosol treatment of respiratory viral disease.

Authors:  V Knight; B E Gilbert
Journal:  Lung       Date:  1990       Impact factor: 2.584

2.  Pharmacokinetics of ribavirin aerosol in mice.

Authors:  B E Gilbert; P R Wyde
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

3.  Efficacy of RD3-0028 aerosol treatment against respiratory syncytial virus infection in immunosuppressed mice.

Authors:  K Sudo; W Watanabe; K Konno; R Sato; T Kajiyashiki; S Shigeta; T Yokota
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

4.  Aerosolized amphotericin B-liposomes for treatment of systemic Candida infections in mice.

Authors:  B E Gilbert; P R Wyde; G Lopez-Berestein; S Z Wilson
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

5.  MegaRibavirin aerosol for the treatment of influenza A virus infections in mice.

Authors:  Brian E Gilbert; Matthew T McLeay
Journal:  Antiviral Res       Date:  2008-02-04       Impact factor: 5.970

6.  Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A/WSN virus.

Authors:  B E Gilbert; P R Wyde; S Z Wilson; R K Robins
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 7.  Respiratory viruses other than influenza virus: impact and therapeutic advances.

Authors:  W Garrett Nichols; Angela J Peck Campbell; Michael Boeckh
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

8.  Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice.

Authors:  B E Gilbert; P R Wyde; S Z Wilson
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 9.  Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Authors:  Tony Velkov; Nusaibah Abdul Rahim; Qi Tony Zhou; Hak-Kim Chan; Jian Li
Journal:  Adv Drug Deliv Rev       Date:  2014-11-12       Impact factor: 15.470

10.  A combination of doxycycline and ribavirin alleviated chikungunya infection.

Authors:  Hussin A Rothan; Hirbod Bahrani; Zulqarnain Mohamed; Teow Chong Teoh; Esaki M Shankar; Noorsaadah A Rahman; Rohana Yusof
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.